TickerFacts.

iTonic Holdings Ltd (ITOC): R&D Expense

Annual figures by period end, from SEC filings.

$459.1K
Year ended 2025-12-31
+84.0%
3-year compound annual growth
2022-12-31: $73.7K2023-12-31: $84.5K2024-12-31: $93.3K2025-12-31: $459.1K$459.1K
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$459.1K+392.0%2026-04-02, From 2025-01-01
2024-12-31$93.3K+10.5%2026-04-02, From 2024-01-01
2023-12-31$84.5K+14.6%2026-04-02, From 2023-01-01
2022-12-31$73.7Kn/a2025-03-20, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
iTonic Holdings Ltd (ITOC)2025-12-31$459.1K+392.0%
Guided Therapeutics Inc (GTHP)2025-12-31$469.0K-10.8%
Nexalin Technology, Inc. (NXL)2025-12-31$1.08M-9.0%
ADM Tronics Unlimited, Inc. (ADMT)2026-03-31$545.0K+5.4%
Neuraxis, Inc (NRXS)2025-12-31$493.6K+13.8%
Nuwellis, Inc. (NUWE)2025-12-31$2.71M-15.5%
Escalon Medical Corp (ESMC)2025-06-30$753.1K+9.4%
CapsoVision, Inc (CV)2025-12-31$18.31M+21.1%
Hyperfine, Inc. (HYPR)2025-12-31$17.45M-22.4%

Compare ITOC, GTHP, NXL, ADMT side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗